Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013 Apr 2, 2013
Rexahn Pharmaceuticals Expands its Intellectual Property Around Class of Potent Anti-cancer Isoquinolinamine Compounds Dec 17, 2012